News
Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care
BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of an agreement for Agilent to acquire BIOVECTRA, a Canadian-based Contract Development and Manufacturing Organization, from H.I.G. Capital for $925 million.
Full service CDMO specializing in biologics, small molecule, nucleic acid modalities, and fill/finish
Our dedicated team leverages microbial fermentation expertise and complex chemistry experience to support our partners’ product development and manufacturing from clinical to commercial stage. We care about your success!
Biologics Manufacturing Excellence
Developing recombinant proteins, plasmid DNA, or antibody fragments in microbial systems? Let us help you accelerate your journey from bench to market.
Small Molecules: From Process Development to Commercial API Manufacturing
Dedication to continuous improvement and ongoing capabilities expansion has made us a valuable long-term partner to our clients.
News
BIOVECTRA Launches Specialized Capabilities in mRNA Drug Product Development and Biomanufacturing
BIOVECTRA celebrated the completion of its $90 million plus biologics expansion at the company’s new state-of-the-art Biomanufacturing Centre with project partners the Government of Canada and Government of Prince Edward Island.
Events
We Are Attending CPHI Milan
Join us October 8-10, 2024 for CPHI Milan. Use the link below to schedule a time to meet with our team. We look forward to seeing you!
Feature Story
Flexibility, creativity, and dedication to make better therapeutics are at the heart of what we do. Read more on recent updates and highlights around our contract drug manufacturing activities.
Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care
CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of an agreement for Agilent to acquire BIOVECTRA, a Canadian-based Contract Development and Manufacturing Organization, from H.I.G. Capital for $925 million. […]
Flexibility, creativity, and dedication to make better therapeutics are at the heart of what we do. Read more on recent updates and highlights around our contract drug manufacturing activities.
We offer robust microbial fermentation capabilities throughout your products life cycle from pilot to commercial scale.
With extensive HPAPI process development and production experience for small and large molecule APIs, we are here to advance your project.
With core expertise in complex microbial fermentation, we continue to add to our ability to accommodate small-batch, pilot, clinical, and commercial production needs.
We are dedicated to producing quality products and effectively managing client projects by bringing process engineering, project management, quality, and regulatory expertise to all we do.
BIOVECTRA offers a selection of high-quality Bioreagents, available in a variety of package sizes as well as GMP grade, to support your project from research and testing to manufacturing scale operations.
Resources
Explore our educational resources! Whether it is our innovative approach to manufacturing biologics using microbial fermentation or insight into the risk management of capital expansions – it is good to know educational information is available. Our Thought Leadership page is the place to find whitepapers, brochures, webinars, and other materials to enhance your knowledge.
Come. Stay. Grow.
BIOVECTRA is a leading pharma and biotech CDMO seeking people of all skillsets, backgrounds and walks of life to join our diverse and growing team. Located in picturesque Prince Edward Island and Nova Scotia, our communities offer a safe and welcoming place for you to advance your career.